GlaxoSmithKline terminated GW501516 development in 2007 after carcinogenicity testing showed cancer acceleration in every tissue studied. WADA banned it in 2009 and issued an unusual explicit public warning. The endurance effects are real. The cancer-accelerating mechanism is also real. This page presents both honestly.
What is Cardarine?
Cardarine (GW501516) produced some of the most impressive endurance data ever seen in an investigational compound. In the landmark 2008 Cell paper by Narkar et al., Cardarine combined with AICAR produced a 75% improvement in running endurance in untrained mice — without any exercise. Alone, Cardarine produced 44% improvement. Human Phase II trials confirmed metabolic effects: improved fat oxidation, reduced triglycerides, improved insulin sensitivity, and increased HDL. The performance and metabolic data was genuinely exceptional.
Then GSK ran mandatory carcinogenicity testing. In all tissues studied — liver, bladder, stomach, skin, tongue, uterus, ovary — GW501516 accelerated the development of cancer. Not caused cancer in otherwise healthy animals. Accelerated pre-existing or chemically induced cancer. GSK terminated development in 2007. WADA banned GW501516 in 2009 and issued an unusual explicit public warning — not standard practice for banned substances.
Despite this, Cardarine has remained one of the most widely used performance compounds in bodybuilding and endurance communities, primarily because the endurance effects are dramatic and the cancer risk is not immediately visible. This page covers Cardarine because evidence-honest coverage of both the performance effects and the cancer risk is more useful than ignoring it. The cancer risk is real. The endurance effects are real. Both must be understood.
How it works
PPAR-delta Agonism — Endurance and Fat Oxidation
PPAR-delta (PPARδ) is a nuclear receptor regulating genes involved in fatty acid oxidation, mitochondrial biogenesis, and fiber type switching in skeletal muscle. PPAR-delta activation drives increased fat oxidation enzymes (CPT1, MCAD), shift from glycolytic to oxidative muscle fibers, increased mitochondrial density via PGC-1α, improved insulin sensitivity via GLUT4 upregulation, and increased HDL via ABCA1. The result is a metabolic state resembling an endurance-trained athlete — without the training.
The Cancer Acceleration Mechanism — Same Receptor, Same Problem
PPAR-delta is expressed throughout the body — including in cancer cells, where PPAR-delta activation promotes proliferation, survival, and angiogenesis (blood vessel growth into tumors). The pro-proliferative effect of PPAR-delta is mechanistically linked to its pro-metabolic effects: both require activation of the same receptor and the same downstream gene expression programs. The cancer-accelerating and performance-enhancing effects of GW501516 are not separable — they come from the same molecular mechanism.
The AICAR Combination
The 75% endurance improvement in the 2008 Cell paper required combining GW501516 with AICAR (the AMPK activator). PPAR-delta activates fat oxidation gene expression. AMPK activates the mitochondrial biogenesis and energy sensing that makes those genes functionally relevant. Together they produce synergistic endurance improvement. This synergy is why AICAR alone produces less dramatic effects than the combination — but AICAR without the cancer-accelerating PPAR-delta component is a safer approach for the endurance goal.
What the research shows
AMPK and PPARdelta agonists are exercise mimetics
Narkar VA et al.
The landmark 'exercise mimetics' paper. In sedentary mice, GW501516 (cardarine) on its own did not boost running endurance — it enhanced endurance when paired with exercise training, reprogramming muscle toward oxidative, fat-burning fibres via PPARδ. (The AMPK activator AICAR, tested alongside, raised endurance ~44% by itself.) This is the study that led WADA to ban both agents.
View on PubMed →GW501516 improves the lipid profile in people with low HDL — Phase II
Olson EJ et al.
Adults with low HDL cholesterol given GW501516 (2.5–10 mg/day) for 12 weeks saw HDL rise (up to ~17%), triglycerides and free fatty acids fall, and LDL drop modestly, shifting toward less-atherogenic particles. Real human confirmation of cardarine's metabolic effects — notably, its development had already been halted over cancer findings in animals, so the story is 'effective but shelved for safety,' not lack of efficacy.
View on PubMed →GSK's mandatory carcinogenicity studies showed GW501516 accelerated cancer development in liver, bladder, stomach, skin, tongue, uterus, and ovary in animal carcinogenicity models. WADA issued an explicit public warning (unusual for a banned substance) in 2013: "Research has shown that GW501516 — and other similar chemicals — caused cancer to develop rapidly in several organs, such as the liver, tongue, skin, urinary bladder, stomach and other organs in animal studies."GSK's scientists found the data disqualifying enough to terminate a profitable drug program.
Open PepperLedger to track your Cardarine protocol →
Free to join. If you proceed, systematic tracking and any available cancer screening is essential. The Researcher understands the risk profile.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT00388180GW501516 effects on body fat and inflammation
- ClinicalTrials.gov · completed · NCT00158899GW501516 in subjects with low HDL cholesterol